Oltar (Glimepiride)

Glimepiride, the active ingredient in Oltar, is a sulfonylurea presented as a tablet for oral use. It helps lower blood glucose levels in adults with type 2 diabetes mellitus. GNH USA supplies Oltar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Glimepiride is used to manage blood glucose in the context of type 2 diabetes mellitus, targeting insulin secretion pathways. - Type 2 Diabetes Mellitus: Improves glycaemic control by stimulating pancreatic beta‑cell insulin release. - Adjunct to Diet and Exercise: Enhances the glucose‑lowering effect of lifestyle measures. - Combination Therapy: Can be combined with metformin or other oral antidiabetics when monotherapy does not achieve target HbA1c.

Glimepiride may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Hypoglycaemia, especially when meals are missed or delayed. - Weight gain. - Nausea or upset stomach. - Headache. - Dizziness.

Serious or Rare Side Effects: - Severe hypoglycaemia with neuroglycopenic symptoms. - Allergic skin reactions such as Stevens‑Stevens‑  . - Hematologic abnormalities: neutropenia  . - Hepatotoxic  . - Acute  . -  .

Glimepiride should be used ​  .

-  . -            "  "